- Book学术

发布求助

文献互助智能选刊最新文献

JEADV clinical practice Pub Date : 2024-12-23 DOI:10.1002/jvc2.590

E. Parriel, C. Bulai-Livideanu, M. Severino-Freire, A. Delpuech, S. Faguer, J. Belliere, A. Huart, C. Paul

{"title":"Rapid clearance of cutaneous lesions with anifrolumab in SLE (systemic lupus erythematosus) and DLE (discoid lupus erythematosus)","authors":"E. Parriel, C. Bulai-Livideanu, M. Severino-Freire, A. Delpuech, S. Faguer, J. Belliere, A. Huart, C. Paul","doi":"10.1002/jvc2.590","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs, including the skin. Activation of the Type I interferon pathway is a key pathophysiological factor in SLE. Discoid lupus erythematosus (DLE) is a chronic cutaneous form of lupus and treatment is challenging with an increased risk of disfigurement and poor quality of life. Treatment of cutaneous manifestations is challenging and current standard therapies remain inadequate. Anifrolumab is a monoclonal antibody that targets the Type 1 interferon receptor subunit 1. Phase III clinical trials (TULIP-1, TULIP-2 and MEDI-546) have demonstrated its efficacy in reducing SLE activity and improving lupus-associated skin manifestations.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>The aim of this retrospective study was to provide information on the early effect of anifrolumab in patients with cutaneous manifestations of lupus with and without systemic involvement.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective study evaluating the early effect of anifrolumab in six patients with refractory cutaneous manifestations of lupus, including those with DLE with and without associated SLE. The outcome measure was the change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score at 1–2 months. Photographs were performed before and after treatment.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The mean baseline CLASI score was 14.2 ± 10.6 (median: 10.5). At 1–2 months, the CLASI score was 5.7 ± 5.3 (median: 3.0). The clinically remarkable efficacy was visible in most patients after the first injection of anifrolumab.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>We observed the rapid efficacy of anifrolumab within the first 2 months in patients with refractory cutaneous manifestations of SLE and CLE. Limitations include the small sample size and lack of a control group. Overall, anifrolumab represents a potential therapeutic option for severe or resistant cutaneous lupus and warrants further investigation. Research is needed to determine its optimal use and efficacy in different cutaneous lupus subtypes.</p>\n </section>\n </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 1","pages":"207-215"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.590","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JEADV clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jvc2.590","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景系统性红斑狼疮（SLE）是一种影响包括皮肤在内的多个器官的自身免疫性疾病。I 型干扰素通路的激活是系统性红斑狼疮的一个关键病理生理因素。盘状红斑狼疮（DLE）是红斑狼疮的一种慢性皮肤病，治疗难度大，毁容风险增加，生活质量低下。皮肤表现的治疗具有挑战性，目前的标准疗法仍然不足。Anifrolumab 是一种针对 1 型干扰素受体亚基 1 的单克隆抗体。III期临床试验（TULIP-1、TULIP-2和MEDI-546）已经证明了它在减少系统性红斑狼疮活动和改善狼疮相关皮肤表现方面的疗效。这项回顾性研究的目的是提供有关阿尼洛单抗对伴有或不伴有系统性受累的狼疮皮肤表现患者的早期疗效的信息。方法对六名难治性狼疮皮肤表现患者（包括伴有或不伴有系统性红斑狼疮的系统性红斑狼疮患者）进行回顾性研究，评估安非鲁单抗的早期疗效。研究结果以1-2个月时皮肤红斑狼疮疾病面积和严重程度指数（CLASI）评分的变化为衡量标准。治疗前后进行拍照。结果 CLASI基线平均得分为14.2 ± 10.6（中位数：10.5）。1-2 个月后，CLASI 评分为 5.7 ± 5.3（中位数：3.0）。大多数患者在首次注射阿尼单抗后就能看到明显的临床疗效。结论我们观察到阿尼单抗在系统性红斑狼疮和系统性红斑狼疮难治性皮肤表现患者的头两个月内迅速见效。不足之处包括样本量较小和缺乏对照组。总之，对于严重或耐药性皮肤狼疮，阿尼洛单抗是一种潜在的治疗选择，值得进一步研究。还需要进行研究，以确定其在不同皮肤狼疮亚型中的最佳用法和疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Rapid clearance of cutaneous lesions with anifrolumab in SLE (systemic lupus erythematosus) and DLE (discoid lupus erythematosus)

查看原文本刊更多论文

Rapid clearance of cutaneous lesions with anifrolumab in SLE (systemic lupus erythematosus) and DLE (discoid lupus erythematosus)

Background

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs, including the skin. Activation of the Type I interferon pathway is a key pathophysiological factor in SLE. Discoid lupus erythematosus (DLE) is a chronic cutaneous form of lupus and treatment is challenging with an increased risk of disfigurement and poor quality of life. Treatment of cutaneous manifestations is challenging and current standard therapies remain inadequate. Anifrolumab is a monoclonal antibody that targets the Type 1 interferon receptor subunit 1. Phase III clinical trials (TULIP-1, TULIP-2 and MEDI-546) have demonstrated its efficacy in reducing SLE activity and improving lupus-associated skin manifestations.

Objectives

The aim of this retrospective study was to provide information on the early effect of anifrolumab in patients with cutaneous manifestations of lupus with and without systemic involvement.

Methods

A retrospective study evaluating the early effect of anifrolumab in six patients with refractory cutaneous manifestations of lupus, including those with DLE with and without associated SLE. The outcome measure was the change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score at 1–2 months. Photographs were performed before and after treatment.

Results

The mean baseline CLASI score was 14.2 ± 10.6 (median: 10.5). At 1–2 months, the CLASI score was 5.7 ± 5.3 (median: 3.0). The clinically remarkable efficacy was visible in most patients after the first injection of anifrolumab.

Conclusions

We observed the rapid efficacy of anifrolumab within the first 2 months in patients with refractory cutaneous manifestations of SLE and CLE. Limitations include the small sample size and lack of a control group. Overall, anifrolumab represents a potential therapeutic option for severe or resistant cutaneous lupus and warrants further investigation. Research is needed to determine its optimal use and efficacy in different cutaneous lupus subtypes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JEADV clinical practice

CiteScore

0.30

自引率

0.00%

发文量